1. Introduction {#sec1-high-throughput-07-00031}
===============

Tuberculosis (TB), caused by the bacterium *Mycobacterium tuberculosis*, is the leading cause of death from an infectious agent worldwide \[[@B1-high-throughput-07-00031]\]. In 2016, an estimated 10.4 million people were infected with TB, leading to the deaths of 1.7 million people \[[@B1-high-throughput-07-00031]\]. Additionally, a third of the global population is latently infected with *M. tuberculosis* and is at risk of developing the active disease. These factors have led to TB being declared as a global health emergency by the World Health Organization \[[@B1-high-throughput-07-00031]\]. Alarmingly, an increasing number of new cases of TB are due to multidrug-resistant (MDR), or extensively drug-resistant (XDR), strains of *M. tuberculosis*, which are not responsive to different first-line TB drugs as well as many other drugs used for the treatment of TB \[[@B1-high-throughput-07-00031],[@B2-high-throughput-07-00031],[@B3-high-throughput-07-00031]\]. This is leading towards a crisis situation in the treatment and/or management of TB, where unless new drugs that are effective against the resistant strains of TB are developed \[[@B4-high-throughput-07-00031],[@B5-high-throughput-07-00031],[@B6-high-throughput-07-00031],[@B7-high-throughput-07-00031]\], it will become very difficult to treat and control the spread of drug-resistant TB in the population. Thus, there is an urgent need for the development of new antimycobacterial drugs, acting via novel mechanisms, which are effective in killing both sensitive as well as resistant strains of *M. tuberculosis*. The availability of genome sequences for *M. tuberculosis* and other mycobacteria has provided a great impetus in the search for new drug targets for development of novel therapeutics for treatment of TB \[[@B5-high-throughput-07-00031],[@B6-high-throughput-07-00031],[@B7-high-throughput-07-00031],[@B8-high-throughput-07-00031],[@B9-high-throughput-07-00031]\]. However, thus far the use of genomics for the identification of novel drug targets and treatment of TB has been explored to only a limited extent \[[@B5-high-throughput-07-00031],[@B6-high-throughput-07-00031],[@B7-high-throughput-07-00031],[@B8-high-throughput-07-00031],[@B9-high-throughput-07-00031]\] and innovative comparative genomic approaches hold much promise of identifying many novel drug targets that can be exploited for the development of a new arsenal of antituberculosis drugs.

For identification of potential drug targets for treatment of tuberculosis, it is important to first understand how the TB causing bacteria are related to, or differ from, other bacteria. In this context, it should be noted that *M. tuberculosis* is a member of the genus *Mycobacterium*, which until recently constituted the sole genus within the family *Mycobacteriaceae*, containing \>188 different named species \[[@B10-high-throughput-07-00031],[@B11-high-throughput-07-00031]\]. While a limited number of species from the genus *Mycobacterium* are important human and animal pathogens (e.g., *M. tuberculosis*, *Mycobacterium leprae* and *Mycobacterium bovis*) \[[@B10-high-throughput-07-00031]\], a vast majority of the species within this genus are nonpathogenic and are found in diverse environments including water bodies, soil, and metalworking fluids \[[@B12-high-throughput-07-00031],[@B13-high-throughput-07-00031],[@B14-high-throughput-07-00031],[@B15-high-throughput-07-00031]\]. Until recently, members of the genus *Mycobacterium* (family *Mycobacteriaceae*), which are a part of the phylum Actinobacteria \[[@B16-high-throughput-07-00031]\], were distinguished from other Actinobacteria and other phyla of bacteria primarily on the basis of their distinct branching in phylogenetic trees based on 16S rRNA or other genes/proteins sequences \[[@B10-high-throughput-07-00031],[@B13-high-throughput-07-00031],[@B17-high-throughput-07-00031]\]. Apart from their branching pattern in phylogenetic trees, no reliable characteristic was known that was specific for either all mycobacteria, or different main groups present within this genus/family, which can reliably differentiate the important groups of pathogenic species from nonpathogenic mycobacteria \[[@B10-high-throughput-07-00031],[@B13-high-throughput-07-00031],[@B17-high-throughput-07-00031]\].

Genome sequences are now available for \>150 of the 188 known mycobacterial species providing an excellent coverage of the genetic diversity existing within the genus *Mycobacterium* and providing a comprehensive resource for robustly elucidating the evolutionary relationships among mycobacterial species using different genome-scale approaches \[[@B18-high-throughput-07-00031],[@B19-high-throughput-07-00031],[@B20-high-throughput-07-00031]\]. Additionally, comparative analyses of genome sequences by innovative approaches provide a rich resource for the identification of novel molecular characteristics that are specifically shared by either all mycobacteria or different major groups within mycobacteria that can now be reliably delineated \[[@B16-high-throughput-07-00031],[@B21-high-throughput-07-00031],[@B22-high-throughput-07-00031],[@B23-high-throughput-07-00031]\]. In this review, I will first present an overview of the overall evolutionary relationships and the new classification scheme for mycobacteria that has emerged from comprehensive phylogenomic and comparative genomic approaches. The remainder of this review focuses on the results from this comparative genomic analysis which has identified \>60 novel and highly-specific molecular characteristics, in the forms of conserved signature inserts and deletions (CSIs) in important proteins, that are exclusive to the *M. tuberculosis* complex of bacteria. The importance and usefulness of the identified CSIs as a new class of potential drug targets for development of novel drugs/compounds that will specifically target the TB-group of bacteria is discussed in the review.

2. Impact of Genomics on Clarifying the Evolutionary Relationships amongst Mycobacteria {#sec2-high-throughput-07-00031}
=======================================================================================

As noted earlier, the genus *Mycobacterium* up to the beginning of this year contained 188 named species, which included several major human pathogens (viz. *M. tuberculosis* and *M. leprae*) as well as a large number of nonpathogenic species \[[@B10-high-throughput-07-00031],[@B24-high-throughput-07-00031]\]. In our recent work, using available genome sequences for 150 mycobacterial species, comprehensive phylogenomics and comparative genome analyses were carried out using multiple independent approaches with the aim of understanding the evolutionary relationships among mycobacterial species \[[@B25-high-throughput-07-00031]\]. Genome sequences permitted construction of phylogenetic trees for mycobacterial species based on multiple large datasets of protein sequences including 1941 core proteins representing the genus *Mycobacterium*, 136 core proteins specific for the phylum Actinobacteria, and 8 other highly conserved proteins that are found in all/most bacteria \[[@B25-high-throughput-07-00031]\]. Phylogenetic trees based on large datasets of protein sequences are known to more accurately portray the evolutionary relationships within any given group of organisms than those based on single gene/protein sequences \[[@B19-high-throughput-07-00031],[@B26-high-throughput-07-00031],[@B27-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B29-high-throughput-07-00031]\]. In all of the constructed trees, *Mycobacterium* species consistently grouped into five strongly supported clades at the highest level, designated as the Tuberculosis-Simiae, Terrae, Triviale, Fortuitum-Vaccae and Abscessus-Chelonae" clades. Some of these clades have also been observed in earlier phylogenetic studies \[[@B10-high-throughput-07-00031],[@B13-high-throughput-07-00031],[@B17-high-throughput-07-00031],[@B25-high-throughput-07-00031]\]. Of these clades, the Tuberculosis-Simiae, Terrae, Triviale clades are largely comprised of slow-growing bacteria (i.e., requiring more than seven days to form colonies), while the other two clades mainly contain rapidly-growing species requiring less than seven days to form colonies \[[@B10-high-throughput-07-00031],[@B24-high-throughput-07-00031]\]. Based on the core genome proteins of mycobacterial species, a pairwise amino acid (aa) identity between these species, which provides a measure of the overall genetic relatedness of the species, was also determined for the *Mycobacterium* species. The results of these analyses also confirmed that the members from each of these five clades are more similar to each other than to the members of the other respective clades \[[@B25-high-throughput-07-00031]\].

In addition to these comprehensive phylogenomic studies, exhaustive comparative genomic analyses were also carried out on protein sequences from mycobacterial genomes to identify molecular signatures in the forms of CSIs and conserved signature proteins (CSPs) that are uniquely shared by either all members of the genus *Mycobacterium* or those exhibiting specificity for members of each of the five identified clades \[[@B16-high-throughput-07-00031],[@B30-high-throughput-07-00031],[@B31-high-throughput-07-00031]\]. The importance of these molecular markers as useful tools for genetic and biochemical studies and for development of novel diagnostics and therapeutics will be discussed later. The results from these comparative genomic analyses have identified 172 molecular signatures consisting of CSIs and CSPs, which are distinctive characteristics of either all of the species from the family *Mycobacteriaceae* or which are specifically shared by different members of the five main clades of mycobacteria delineated by phylogenomic analyses. These molecular signatures provide strong independent evidence that the species from the five main observed clades of mycobacteria are genetically distinct from each other while also offering a reliable means for the demarcation of these groups in molecular terms. A summary diagram depicting the five main clades of mycobacteria and their interrelationships, which has emerged based on genomic analyses is presented in [Figure 1](#high-throughput-07-00031-f001){ref-type="fig"} \[[@B25-high-throughput-07-00031]\]. The numbers of identified molecular markers which are specific for different main clades as well various intermediate branch-points are also shown in this figure.

Based on the compelling evidence amassed from different genomic scale analyses, all of which strongly supported the existence of the five main clades within the genus *Mycobacterium* as depicted in [Figure 1](#high-throughput-07-00031-f001){ref-type="fig"}, the genus *Mycobacterium* has now been divided into five different genera. In the new classification scheme for the family *Mycobacteriaceae*, the genus name *Mycobacterium* is limited to only members of the Tuberculosis-Simiae clade \[[@B25-high-throughput-07-00031]\]. The delimited genus *Mycobacterium* continues to retain all of the major human and animal pathogenic species including *M. tuberculosis*, *M. leprae*, *M. bovis*, etc. The species belonging to the Fortuitum-Vaccae clade, which are primarily environmental species, are now placed into a new genus *Mycolicibacterium*, whereas the species from the Terrae and Triviale clades, which are also nonpathogenic, except occasional association with animal hosts or human patients, are now assigned to two new genera *Mycolicibacter* and *Mycolicibacillus*, respectively \[[@B25-high-throughput-07-00031]\]. Lastly, the species from the Abscessus-Chelonae, some of which are associated with lung, skin and soft tissue infections are transferred into a new genus *Mycobacteroides* \[[@B25-high-throughput-07-00031]\].

In the new classification scheme for mycobacteria, all of the major human and animal pathogenic species are retained in the delimited genus *Mycobacterium* and they are separated from other genera of mycobacterial species, which are comprised of species that are either non-pathogenic or are of lesser clinical significance \[[@B25-high-throughput-07-00031]\]. With the explicit division of the mycobacterial species into these distinct groups or genera, attention can now be focused on the unique genetic and molecular characteristics that differentiate the members of these different groups of microbes. Although the new classification scheme represents a significant advancement in terms of clarifying the genetic diversity that exist within the family *Mycobacteriaceae*, two of the main genera comprising this family i.e., *Mycobacterium* and *Mycolicibacterium*, consisting respectively of the slow-growing and fast-growing mycobacterial species, are still very large and genetically diverse. Of these, the new genus *Mycobacterium* contains \>70 species and within it a number of different species groups viz. "Tuberculosis complex", "Avium complex", "Gordonae clade", "Kansasii clade", "Simiae clade", and a clade of mycolactone-producing mycobacteria, are informally recognized \[[@B10-high-throughput-07-00031],[@B17-high-throughput-07-00031],[@B19-high-throughput-07-00031],[@B24-high-throughput-07-00031]\]. Additionally, a large number of species from this genus including *M. leprae*, are not part of any of these clades. As the genus *Mycobacterium* contains some of the most significant human and animal pathogens, it is necessary to obtain a more reliable understanding of the evolutionary relationships among this group of bacteria in order to identify characteristics that differentiate the tuberculosis causing bacteria from other members of this genus.

Based on the branching patterns of species in different phylogenetic trees constructed in our earlier work \[[@B25-high-throughput-07-00031]\], as well as additional phylogenomics and comparative genomics studies that we have carried out on these bacteria (to be described later), a good understanding of the evolutionary relationships among different species that comprise the new (delimited) genus *Mycobacterium* can now be acquired. Based on the results of these studies, at least 11 distinct species clades can be distinguished within the genus *Mycobacterium* based on their branching in phylogenetic trees and identified molecular signatures ([Figure 2](#high-throughput-07-00031-f002){ref-type="fig"}). A number of these species' clades are similar to those indicated in earlier studies \[[@B10-high-throughput-07-00031],[@B24-high-throughput-07-00031]\]. Of particular interest in the present context is the clade consisting of the tuberculosis-complex of species. The tuberculosis-complex consists of a tightly-clustered group of ten species (viz. *M. tuberculosis*, *Mycobacterium africanum*, *Mycobacterium bovis*, *Mycobacterium canettii*, *Mycobacterium caprae*, *Mycobacterium microti*, *Mycobacterium mungi*, *Mycobacterium orygis*, *Mycobacterium pinnipedii* and *Mycobacterium suricattae*), all of which are human or animal pathogens. Genome sequences are now available for most of the species from this group. In phylogenetic trees (see [Figure 2](#high-throughput-07-00031-f002){ref-type="fig"}), the tuberculosis-complex of species are separated from all other mycobacteria by a long branch and the species *Mycobacterium shinjukuense* and *Mycobacterium lacus*, which are rarely pathogenic \[[@B32-high-throughput-07-00031],[@B33-high-throughput-07-00031]\], are indicated to be their closest relatives. In view of the long-branch (i.e., genetic distance) that separates the tuberculosis-complex of species from all other bacteria, it is expected that this group of bacteria should differ significantly from all other mycobacteria in terms of their genetic and biochemical characteristics. Hence, we have carried out detailed comparisons of the sequences for different proteins from the genomes of tuberculosis-complex of species and other mycobacteria to identify novel molecular signatures such as CSIs, which are specific for the *M. tuberculosis* complex of species. The genetic and biochemical significance of the CSIs and a summary of the results obtained from our comparative genomics studies are described below.

3. Genetic and Biological Significance of the Conserved Signature Indels {#sec3-high-throughput-07-00031}
========================================================================

Conserved signature indels represent an important class of molecular markers, whose discovery has been enabled by the growing availability of genome sequences \[[@B25-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B31-high-throughput-07-00031],[@B34-high-throughput-07-00031],[@B35-high-throughput-07-00031]\]. Although the inserts and deletions are commonly present in gene/protein sequences, only a small subset of these indels represent CSIs that are found to be useful for the different applications indicated here \[[@B29-high-throughput-07-00031],[@B31-high-throughput-07-00031]\]. The indels that constitute CSIs are generally of fixed lengths, present at specific positions in particular genes/proteins, and are flanked on both sides by conserved regions to ensure that they constitute reliable characteristics \[[@B25-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B31-high-throughput-07-00031],[@B34-high-throughput-07-00031],[@B35-high-throughput-07-00031]\]. As the CSIs in genes/proteins sequences result from rare genetic changes, when a particular CSI is specifically shared by a phylogenetically-related group of organisms, its presence is most parsimoniously accounted by the genetic change leading to the CSI occurring in a common ancestor of the group followed by vertical inheritance of this genetic change by other group members \[[@B25-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B31-high-throughput-07-00031],[@B34-high-throughput-07-00031],[@B35-high-throughput-07-00031]\]. Based upon the presence or absence of a CSI in outgroup (i.e., ancestral) species, it is also possible to infer whether a given CSI represents an insertion or a deletion. Extensive earlier work on CSIs provides evidence that both large as well as small CSIs (even a one aa insert/deletion in protein sequence) are reliable molecular markers and they both exhibit a high degree of predictive ability to be present in other members of the indicated groups for which sequence information may be lacking \[[@B16-high-throughput-07-00031],[@B21-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B29-high-throughput-07-00031],[@B35-high-throughput-07-00031],[@B36-high-throughput-07-00031],[@B37-high-throughput-07-00031]\]. In view of the reliability and exclusive presence of specific CSIs in a particular group of organisms, the CSIs now provide a dependable means for the demarcation of prokaryotic taxa of different ranks (ranging from genus to phylum) in molecular terms \[[@B25-high-throughput-07-00031],[@B28-high-throughput-07-00031],[@B29-high-throughput-07-00031],[@B38-high-throughput-07-00031]\]. Furthermore, due to the specificity of the CSIs for a given group of organisms, the genetic/molecular changes introduced by them are predicted to be important for the CSI-containing organisms and this prediction has been confirmed experimentally for several studied CSIs \[[@B39-high-throughput-07-00031],[@B40-high-throughput-07-00031],[@B41-high-throughput-07-00031],[@B42-high-throughput-07-00031]\]. As the genotype determines and controls the phenotype, the identified CSIs also provide important genetic/biochemical tools for discovering novel properties that are important to and uniquely shared by different groups of organisms for which these CSIs are specific.

4. Conserved Signature Indels Specific for the *M. tuberculosis* Complex of Organisms {#sec4-high-throughput-07-00031}
=====================================================================================

The results of our comparative genomic studies on mycobacterial genomes have identified 63 CSIs in important proteins that are distinctive characteristics of the tuberculosis-complex of species. Sequence information for three of these CSIs are presented in [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"} and [Figure 4](#high-throughput-07-00031-f004){ref-type="fig"}. [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"}A shows partial sequence alignment of the protein UDP-*N*-acetylenolpyruvoylglucosamine reductase (MurB), which plays an essential role in the biosynthesis of peptidoglycan in both Gram-positive and Gram-negative bacteria by catalyzing the formation of UDP-*N*-acetyl muramic acid from UDP- *N*-acetyl glucosamine \[[@B43-high-throughput-07-00031],[@B44-high-throughput-07-00031]\]. In MurB protein, a four aa insert in a highly-conserved region is uniquely found in all nine sequenced species from the tuberculosis-complex of organisms, but it is not present in any other mycobacteria or actinobacteria. The results of Himar1-based transposon mutagenesis indicate that the *murB* gene is essential for in vitro growth of *M. tuberculosis* H37Rv \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\]. As MurB has no known eukaryotic homologues, it provides a unique antibacterial target \[[@B44-high-throughput-07-00031]\].

In [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"}B, partial sequence alignment is presented of a protein annotated as putative 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH). In this protein, a seven aa insertion in a conserved region is uniquely found in all nine sequenced *M. tuberculosis* complex of organisms, but not in any other mycobacteria. The CysH protein catalyzes the reduction of activated sulfate into sulfite and plays an important role in the sulfate activation pathway \[[@B47-high-throughput-07-00031]\]. This protein is actively expressed in macrophages during the latent phase of infection with *M. tuberculosis* and appears to be required for the survival of tuberculosis bacteria in the macrophages. The gene for the CysH protein is also found to be essential for in vitro growth of H37Rv strain of *M. tuberculosis* \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\]. Disruption of *cysH* gene in *M. tuberculosis* has been reported to cause auxotrophy for cysteine and methionine and attenuated virulence \[[@B48-high-throughput-07-00031]\]. Although a homolog of the CysH protein is present in human, it lacks the N-terminal region of the protein, where this large insertion is found. Thus, the region of the protein shown in [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"}B is not found in humans and the large insert present in this region is a specific characteristic of the *M. tuberculosis* complex of organisms. We also show in [Figure 4](#high-throughput-07-00031-f004){ref-type="fig"} an example a protein where a 12 aa long deletion is present in a LytR family transcriptional regulatory protein in the *M. tuberculosis* related organisms. Interestingly, while this large CSIs is present in all other sequenced species from the *M. tuberculosis* complex (eight out of nine sequenced species), it is not present in *M. canettii*, which branches earlier in comparison to the other species from this complex in phylogenetic trees ([Figure 2](#high-throughput-07-00031-f002){ref-type="fig"}). Thus, this large deletion while providing a highly-specific molecular marker for the *M. tuberculosis* and its close relatives serves to differentiate them from *M. canettii*, which is also a part of the tuberculosis-complex of species.

In addition to the CSIs shown in [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"} and [Figure 4](#high-throughput-07-00031-f004){ref-type="fig"}, our comparative genomic analyses have identified 60 other CSIs in proteins involved in many diverse functions. A summary of some characteristics of these CSIs and the proteins in which they are found is shown in [Table 1](#high-throughput-07-00031-t001){ref-type="table"}. Detailed sequence information for the three CSIs shown in [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"} and [Figure 4](#high-throughput-07-00031-f004){ref-type="fig"} and the other 60 identified CSIs are provided in [Figures S1--S63](#app1-high-throughput-07-00031){ref-type="app"}. As seen from [Table 1](#high-throughput-07-00031-t001){ref-type="table"}, the identified CSIs are of different lengths and they are found in proteins involved in a broad range of cellular functions including cell wall synthesis, drug and ion transport, DNA replication, transcription and repair, protein translation, biosynthesis of cofactors and coenzymes such as ubiquinone and menaquinone, and proteins playing important roles in a variety of metabolic and regulatory pathways. In addition to the proteins with annotated cellular functions, a significant proportion of proteins harboring these CSIs are conserved proteins, with no information available regarding their cellular functions. The last column in [Table 1](#high-throughput-07-00031-t001){ref-type="table"} provides information based on Himar1-transposon mutagenesis studies indicating whether the genes for these proteins were found to be essential or nonessential for the in vitro growth of *M. tuberculosis* \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\].

As seen from [Table 1](#high-throughput-07-00031-t001){ref-type="table"}, the genes for a significant proportion (\~20%) of the proteins, where these CSIs are found have been found to be essential for the in vitro growth/function of *M. tuberculosis* strain H37Rv \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\]. Besides MurB and CysH, some of the other genes/proteins containing CSIs that are essential for the growth of *M. tuberculosis* include, MenE protein (an acetyl coenzyme A (acyl-CoA) synthetase (ligase) playing an essential role in menaquinone biosynthesis pathway \[[@B49-high-throughput-07-00031],[@B50-high-throughput-07-00031]\], a putative adenosine triphosphate (ATP) dependent DNA ligase (Mt-Lig) \[[@B51-high-throughput-07-00031]\], polyketide synthase protein (Pks8) involved in the biosynthesis of mycolic acid \[[@B52-high-throughput-07-00031],[@B53-high-throughput-07-00031]\], NadE (nicotinamide adenine dinucleotide (NAD+) synthetase) protein catalyzing the last step of NAD biosynthesis \[[@B54-high-throughput-07-00031]\], ribonuclease E playing an important role in RNA processing and decay \[[@B55-high-throughput-07-00031]\] and folylpolyglutamate synthase (FPGS or FolC) protein, involved in the conversion of folates into polyglutamates derivatives \[[@B56-high-throughput-07-00031],[@B57-high-throughput-07-00031]\]. Folate pathway is an established target for development of antimicrobials \[[@B58-high-throughput-07-00031]\] and it is of interest to note that missense mutations within the dihydropteroate binding pocket of FolC confer resistance to *para*-aminosalicylic acid (PAS) in clinical isolates of *M. tuberculosis* and confer resistance to PAS, which is an important agent in the treatment of multidrug-resistant tuberculosis \[[@B56-high-throughput-07-00031],[@B57-high-throughput-07-00031],[@B58-high-throughput-07-00031]\]. Some of the other proteins containing CSIs that are essential for the growth of *M. tuberculosis* include propionyl-CoA carboxylase subunit beta chain playing an essential role in the catabolic pathway of odd-chain fatty acids, isoleucine, threonine, methionine, and valine \[[@B59-high-throughput-07-00031],[@B60-high-throughput-07-00031]\], putative phosphor-sugar (glucosamine) mutase involved in glycolysis and sugar metabolism \[[@B61-high-throughput-07-00031]\], DNA topoisomerase I, TOPA (omega-protein) involved in relaxation of DNA \[[@B62-high-throughput-07-00031]\], indolylacetylinositol arabinosyltransferase (EmbB), involved in the biosynthesis of cell wall arabinogalactan and lipoarabinomannan and a well-established target for the drug ethambutol \[[@B63-high-throughput-07-00031],[@B64-high-throughput-07-00031]\], and guanosine triphosphatase (GTPase) Era which has intrinsic GTPase activity and is a regulator of cell growth \[[@B65-high-throughput-07-00031]\].

The CSIs in protein structures are generally located in surface-exposed loops of the proteins \[[@B39-high-throughput-07-00031],[@B40-high-throughput-07-00031],[@B66-high-throughput-07-00031],[@B67-high-throughput-07-00031],[@B68-high-throughput-07-00031]\]. Structures of several proteins in which the CSIs have been identified in this work are now available for either *M. tuberculosis* or other organisms \[[@B69-high-throughput-07-00031],[@B70-high-throughput-07-00031]\]. Based on the latter structures, structures of the corresponding *M. tuberculosis* proteins can be deduced using the homology modelling technique \[[@B71-high-throughput-07-00031]\]. We have examined the structural locations of the two CSIs shown in [Figure 2](#high-throughput-07-00031-f002){ref-type="fig"} in the corresponding proteins structures. For the MurB protein, its structure has been solved from *M. tuberculosis* (PDB ID: 5JZX) \[[@B72-high-throughput-07-00031]\]. The four aa insertion in this protein which is specific for the *M. tuberculosis* complex of organisms (shown in red) forms a distinct lobe on the surface of the protein ([Figure 5](#high-throughput-07-00031-f005){ref-type="fig"}A). Using the structure of MurB protein from *M. tuberculosis* as a template, a homology model of this protein was also created for the *Mycobacterium angelicum homolog*, which lacks this CSI. The homology modelling was carried out as in our earlier work \[[@B39-high-throughput-07-00031],[@B66-high-throughput-07-00031],[@B73-high-throughput-07-00031]\]. A close up of the structural comparison of the CSI-containing region for MurB from *M. tuberculosis* (colored in green) and *M. angelicum* (shown in cyan) is presented in [Figure 5](#high-throughput-07-00031-f005){ref-type="fig"}B. As seen, while the rest of the structures show nearly perfect overlap, the CSI in the *M. tuberculosis* protein (highlighted in red), extends an α-helix and forms part of a surface-exposed loop.

The structure of the CysH (3′-phosphoadenosine 5′-phosphosulfate reductase) protein from *M. tuberculosis* is not known. However, the structure of this protein has been solved from *Pseudomonas aeruginosa* (PDB ID: 2GOY) \[[@B74-high-throughput-07-00031]\]. Based on the latter structure, a homology model of the CysH protein was created from *M. tuberculosis*. As the seven aa insertion is not present in the *P. aeruginosa* protein, it was modelled \[[@B39-high-throughput-07-00031],[@B66-high-throughput-07-00031],[@B73-high-throughput-07-00031]\]. The structures of the modelled CysH protein from *M. tuberculosis* ([Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}A), its solved structure from *P. aeruginosa* ([Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}B), and a close up of the aligned structures for the CSI region from the two proteins, are shown in [Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}. As seen from [Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}C, the 7 aa CSI in the *M. tuberculosis* protein (shown in red) forms a surface-exposed loop/lobe in the protein structure ([Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}A,C), that is lacking in the organisms not containing this CSI ([Figure 6](#high-throughput-07-00031-f006){ref-type="fig"}B).

5. Significance and Applications of the Tuberculosis-Complex Specific Conserved Signature Indels for Development of Novel Diagnostics and Therapeutics {#sec5-high-throughput-07-00031}
======================================================================================================================================================

Most studied CSIs exhibit a number of unique characteristics, which makes them potentially useful means for development of novel and specific diagnostic tests as well as potential targets for development of new classes of therapeutics. The usefulness of the CSIs for development of novel diagnostic tests is based on the observation that the CSIs are present in conserved regions of the genes/proteins and they exhibit a high degree of specificity for a given group of organisms \[[@B21-high-throughput-07-00031],[@B23-high-throughput-07-00031],[@B37-high-throughput-07-00031],[@B75-high-throughput-07-00031],[@B76-high-throughput-07-00031]\]. Earlier work on CSIs provides compelling evidence that these molecular markers are highly specific characteristics of a given group of organisms \[[@B21-high-throughput-07-00031],[@B23-high-throughput-07-00031],[@B37-high-throughput-07-00031],[@B75-high-throughput-07-00031],[@B76-high-throughput-07-00031]\]. Further, these molecular characteristics are not only specifically found in the available sequences from a given group of organisms, but that they also exhibit a high degree of predictive ability to be found in other group members for which sequence information is lacking at present \[[@B16-high-throughput-07-00031],[@B31-high-throughput-07-00031],[@B35-high-throughput-07-00031],[@B38-high-throughput-07-00031]\]. In view of these characteristics, novel diagnostic tests for the detection of TB, based on the sequence regions harboring these CSIs, can be developed by means of different commonly used techniques e.g., polymerase chain reaction (PCR-based), real-time quantitative PCR (q-PCR-based), pyrosequencing, immunological or antibody-based methods, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), aptamer-based methods, as well as in silico identification of the CSI-containing organisms in genomic and metagenomic sequences. As examples of the utility of CSIs for development of novel diagnostic tests, the CSIs specific for *Bacillus anthracis* and *Escherichia coli* O157/H7 have been successfully used for the development of highly-specific diagnostic tests for these important pathogens \[[@B75-high-throughput-07-00031],[@B76-high-throughput-07-00031]\]. Although great advancements have been made in the detection of TB and multiple diagnostic tests are available for this purpose \[[@B2-high-throughput-07-00031],[@B3-high-throughput-07-00031],[@B77-high-throughput-07-00031],[@B78-high-throughput-07-00031]\], most of these tests are either slow, lack specificity or are costly. Given that TB is most prevalent in low to middle income countries, there is a need for developing sensitive, specific and inexpensive tests for detection of TB \[[@B9-high-throughput-07-00031],[@B78-high-throughput-07-00031]\].

Besides their presence in conserved regions and specificity for a particular group of organisms, most studied CSIs exhibit a number of other characteristics that make them potentially useful means for development of novel therapeutics. The first of these characteristics is that the CSIs in protein sequences are predicted to play important functional roles in the organisms in which they are found \[[@B41-high-throughput-07-00031],[@B42-high-throughput-07-00031],[@B66-high-throughput-07-00031]\]. It has been experimentally shown for a number of CSIs that the removal of the CSIs from studied genes/proteins, or any significant changes in their sequences by genetic means affected/inhibited the growth of the CSI-containing organisms \[[@B35-high-throughput-07-00031],[@B41-high-throughput-07-00031]\]. These studies also demonstrated that both large as well as small CSIs (even one aa insert or deletion) play important roles in the protein's function \[[@B35-high-throughput-07-00031],[@B41-high-throughput-07-00031]\]. Another important characteristic of the CSIs is that nearly all studied CSIs (including the examples described here) are located in the surface-exposed loops of the proteins, located away from the protein's active or substrate binding sites \[[@B39-high-throughput-07-00031],[@B40-high-throughput-07-00031],[@B66-high-throughput-07-00031]\]. Extensive earlier work indicates that the surface loops in protein sequences play important roles in facilitating novel protein-protein or protein-ligand interactions \[[@B39-high-throughput-07-00031],[@B66-high-throughput-07-00031],[@B67-high-throughput-07-00031],[@B68-high-throughput-07-00031],[@B79-high-throughput-07-00031]\]. Based on the above observations, the most plausible explanation to account for the presence and functional roles played by different CSIs that are specific for the MTB-complex of organisms is that they are involved in mediating novel interactions (viz. protein-protein or protein-ligand) of the CSI-containing proteins in the MTB-complex of organisms \[[@B39-high-throughput-07-00031],[@B41-high-throughput-07-00031],[@B66-high-throughput-07-00031],[@B67-high-throughput-07-00031],[@B68-high-throughput-07-00031],[@B79-high-throughput-07-00031]\]. It is postulated that these interactions, which are predicted to be specific for the MTB-complex of organisms, serve to differentiate these organisms from other mycobacteria which do not contain the CSIs. Further, it is suggested that the interactions mediated by the CSIs confer selective advantage to the MTB-complex of organisms in their natural habitat \[[@B41-high-throughput-07-00031]\]. The selective advantages conferred by these interactions could include the ability to obtain nutrients in a nutrient-deficient environment, protection against host defense mechanisms, or breaching of the host defenses to enable its propagation (i.e. virulence). The blocking or inhibition of these interactions is thus expected to affect the growth or virulence of the MTB-complex organisms.

The above observations indicate that the CSI-containing regions of the *M. tuberculosis* proteins can also serve as potential means for the screening of novel compounds, which are specifically targeted towards this group of organisms. Since the CSIs are located in surface loops of the proteins, they provide readily accessible sites for binding of small molecules. Further as noted earlier, for most of the proteins which contain the *M. tuberculosis*-specific CSIs, their homologs are either not found in humans, or if they are present they generally do not contain the indicated CSIs. Based on these observations, it is hypothesized that screening for small molecules, which bind specifically to the CSI-containing regions of the *M. tuberculosis* proteins should lead to identification of a class of compounds which will interfere with the cellular functions of the CSIs, and such compounds would likely specifically affect the growth of the MTB-complex of organisms. Mutational studies indicate that only about 20--25% of the genes/proteins containing the CSIs specific for the MTB group of organisms are essential for the in vitro growth of *M. tuberculosis* ([Table 1](#high-throughput-07-00031-t001){ref-type="table"}) \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\]. However, growth of the cells *in vitro* does not provide an accurate measure of the growth of the organism in its natural habitat, which is impacted upon by many factors \[[@B80-high-throughput-07-00031]\]. As the CSIs in all of the proteins described here are specific for the MTB group of organisms, it is likely that they all play specific roles in the functioning/survival of *M. tuberculosis* in the host environment by enabling functional interactions with other essential proteins/components. Thus, blocking the functions of CSIs in these other "non-essential" proteins by compounds that binds specifically to them is also expected to affect the growth or virulence of *M. tuberculosis* and related organisms within their hosts.

To test the feasibility of using CSIs as possible drug targets, it is important to have the structural information for different *M. tuberculosis* proteins in which the identified CSIs are found. Although the structures of some *M. tuberculosis* proteins containing the CSIs are now available in the RCSB Protein Data Bank \[[@B69-high-throughput-07-00031],[@B70-high-throughput-07-00031],[@B81-high-throughput-07-00031],[@B82-high-throughput-07-00031]\], further work on solving the structures of the proteins in which the large CSIs specific for the MTB-complex of organisms are found is necessary. Based on the structures of the proteins containing the CSIs as well as lacking the CSIs, the location of the CSI-containing regions in the protein structures can be reliably determined. High-throughput virtual screening of small molecule libraries can then be carried out to identify lead compounds \[[@B47-high-throughput-07-00031],[@B83-high-throughput-07-00031],[@B84-high-throughput-07-00031]\] which bind with high affinity to only the CSI-containing regions in the proteins. Most of the work on drug discovery in the past, including structure-based drug design, has focused heavily on identification of compounds which inhibit growth by binding to the active sites of the proteins \[[@B7-high-throughput-07-00031],[@B8-high-throughput-07-00031],[@B9-high-throughput-07-00031],[@B50-high-throughput-07-00031],[@B85-high-throughput-07-00031],[@B86-high-throughput-07-00031]\]. In contrast, identification of small molecules which inhibit cell growth or cellular function by interfering with the functions of the CSIs could represent a potentially new class of compounds that are active against the MTB-complex of organisms. Although the concept of using CSIs as possible drug-target has been suggested previously \[[@B87-high-throughput-07-00031]\], the potential of these novel genetic/biochemical characteristics for new drug development remains unexplored.

6. Conclusions {#sec6-high-throughput-07-00031}
==============

Phylogenomic and comparative analyses of mycobacterial genomes sequences have provided important insights into the evolutionary relationships among this large and important group of microorganisms. The results reviewed here reveal that the TB-causing bacteria constitute a small group differing from all other mycobacteria in numerous regards. Comparative analyses of protein sequences from mycobacteria have identified 63 conserved signature indels in important proteins that are uniquely found in different members of the TB-complex of bacteria. Several characteristics of the CSIs reviewed here suggest that these novel genetic features could serve as an unexplored means for development of novel diagnostics and also as potential means for development of a new class of therapeutics specifically targeting the MTB-group of organisms.

The following are available online at <http://www.mdpi.com/2571-5135/7/4/31/s1>, Figure S1: Partial sequence alignment of a conserved region of the UDP-*N*-acetylenolpyruvoyl-glucosamine reductase (MurB) protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S2: Partial sequence alignment of a conserved region of the 3′-phosphoadenosine 5′-phosphosulfate reductase CYSH protein showing a seven amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S3: Partial sequence alignment of a conserved region of the transcriptional regulator protein showing a twelve amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S4: Partial sequence alignment of a conserved region of the propionyl-CoA carboxylase betachain 5 protein showing a one amino acid deletion that is specific for most members of the "Tuberculosis" clade and is absent form most other *Mycobacteriaceae*; Figure S5: Partial sequence alignment of a conserved region of the O-succinylbenzoic acid-CoA ligase MenE protein showing a two amino acid insertion that is specific for members of the "Tuberculosis" clade and absent in most other *Mycobacteriaceae*; Figure S6: Partial sequence alignment of a conserved region of a ligase protein showing a four aminoacid insertion that is specific for members of the "Tuberculosis" clade and absent from most other *Mycobacteriaceae*; Figure S7: Partial sequence alignment of a conserved region of the arabinosyltransferase protein showinga three amino acid insertion that is specific for members of the "Tuberculosis" clade and absent from most other *Mycobacteriaceae*; Figure S8: Partial sequence alignment of a conserved region of the GTPase Era protein showing a oneamino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S9: Partial sequence alignment of a conserved region of the primosome assembly protein PriA showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S10: Partial sequence alignment of a conserved region of the phospho-sugar mutase/MRSAprotein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade and absent from most other *Mycobacteriaceae*; Figure S11: Partial sequence alignment of a conserved region of the polyketide synthase Pks8 protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S12: Partial sequence alignment of a conserved region of the Glutamine-dependent NAD(+) synthetase protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S13: Partial sequence alignment of a conserved region of the ribonuclease E protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S14: Partial sequence alignment of a conserved region of the ribonuclease E protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S15: Partial sequence alignment of a conserved region of the DNA topoisomerase I protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S16: Partial sequence alignment of a conserved region of the metal cation transporting ATPaseH protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S17: Partial sequence alignment of a conserved region of an acyltransferase protein showing afour amino acid insertion that is specific for members of the "Tuberculosis" clade and absent from most other *Mycobacteriaceae*; Figure S18: Partial sequence alignment of a conserved region of an alpha-amylase protein showing aone amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S19: Partial sequence alignment of a conserved region of the hypothetical proteinIQ48_14915 showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S20: Partial sequence alignment of a conserved region of the hypothetical proteinCAB90_01059 showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S21: Partial sequence alignment of a conserved region of the transcriptional regulator proteinshowing a one amino acid deletion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S22: Partial sequence alignment of a conserved region of the hypothetical protein IU12_21070 showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S23: Partial sequence alignment of a conserved region of the hypothetical protein IU14_19860 showing a two amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S24: Partial sequence alignment of a conserved region of amembrane protein showing an eight amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S25: Partial sequence alignment of a conserved region of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S26: Partial sequence alignment of a conserved region of a transmembrane protein showing a three amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S27: Partial sequence alignment of the hypothetical protein ERS181347_00724 showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S28: Partial sequence alignment of a conserved membrane protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S29: Partial sequence alignment of the fructose-bisphosphate aldolase protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S30: Partial sequence alignment of the fructose-bisphosphate aldolase protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S31: Partial sequence alignment of a conserved protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S32: Partial sequence alignment of the exonuclease V subunit alpha protein showing a two amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S33: Partial sequence alignment of the multidrug resistance protein EmrB showing a three amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S34: Partial sequence alignment of the Hypothetical protein ERS024213_05484 showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S35: Partial sequence alignment of the LuxR family transcriptional regulator protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S36: Partial sequence alignment of the polyprenyl-diphosphate synthase GrcC protein showing a three amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S37: Partial sequence alignment of the polyprenyl-diphosphate synthase GrcC protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S38: Partial sequence alignment of a cold-shock protein showing a two amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S39: Partial sequence alignment of a transcriptional regulator protein showing a one amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S40: Partial sequence alignment of the hypothetical protein IQ40_04435 showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S41: Partial sequence alignment of an esterase protein showing a one amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S42: Partial sequence alignment of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S43: Partial sequence alignment of a DEAD/DEAH box helicase protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S44: Partial sequence alignment of a phosphoglycerate mutase protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S45: Partial sequence alignment of a hypothetical protein CAB90_02390 showing a two amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S46: Partial sequence alignment of the glycerol-3-phosphate dehydrogenase protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S47: Partial sequence alignment of the GTP-binding protein LepA showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S48: Partial sequence alignment of the type I restriction/modification system specificity determinant HsdS protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S49: Partial sequence alignment of the hypothetical protein IQ38_12515 showing a two amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S50: Partial sequence alignment of the polyketide synthase protein showing a three amino acid insertion that is specific for most members of the "Tuberculosis" clade; Figure S51: Partial sequence alignment of a lipase protein showing a one amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S52: Partial sequence alignment of a secreted protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade; Figure S53: Partial sequence alignment of the DNA polymerase IV protein showing a one amino acid deletion that is specific for most members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S54: Partial sequence alignment of an ATP-dependent DNA helicase protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S55: Partial sequence alignment of an ATP-dependent DNA helicase protein showing a one amino acid deletion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S56: Partial sequence alignment of an ATPase protein showing a one amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S57: Partial sequence alignment of a DNA glycosylase protein showing a four amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S58: Partial sequence alignment of the hypothetical protein IQ47_16905 showing a three amino acid insertion that is specific for most members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S59: Partial sequence alignment of a hydrolase protein showing a three amino acid insertion that is specific for members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S60: Partial sequence alignment of the hypothetical protein RN11_1864 showing an eight amino acid insertion that is specific for most members of the "Tuberculosis" clade and is absent from most other *Mycobacteriaceae*; Figure S61: Partial sequence alignment of the acyl-CoA dehydrogenase FadE27 protein showing an eight amino acid insertion that is specific for members of the "Tuberculosis" clade; Figure S62: Partial sequence alignment of an oxidoreductase protein showing an eleven amino acid deletion that is specific for most members of the "Tuberculosis" clade; Figure S63: Partial sequence alignment of the hypothetical protein IQ42_20035 showing a two amino acid deletion that is specific for most members of the "Tuberculosis" clade.
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![A compressed tree showing the main clades of mycobacteria observed in phylogenomic trees and molecular markers that have been identified for different clades. The tree shown is based on 1941 core proteins from the genomes of 150 *Mycobacteriaceae* species \[[@B25-high-throughput-07-00031]\]. The terms CSIs and CSPs refer to conserved signature indels and conserved signature proteins, respectively, which are specific for the species from the observed clades. Comprehensive analyses of genome sequences have led to division of the family *Mycobacteriaceae* (genus *Mycobacterium*) into five different genera as indicated here \[[@B25-high-throughput-07-00031]\].](high-throughput-07-00031-g001){#high-throughput-07-00031-f001}

![A compressed phylogenetic tree showing the main clades observed within the delimited genus *Mycobacterium* in a phylogenetic tree. The tree shown is based on 136 proteins commonly shared by members of the phylum Actinobacteria. The tree was constructed as described in earlier work \[[@B25-high-throughput-07-00031]\] and the main species groupings observed are collapsed, except those from the *M. tuberculosis*-related group of bacteria. The group of species that is commonly referred to as the tuberculosis-complex is marked. All of the CSIs described in this work are specific for the tuberculosis-complex of bacteria.](high-throughput-07-00031-g002){#high-throughput-07-00031-f002}

![Partial sequence alignments of the proteins (**A**) UDP-*N*-acetylenolpyruvoyl-glucosamine reductase (MurB) and (**B**) 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH), containing conserved inserts of four amino acid (aa) and seven aa (boxed), respectively, which are uniquely found in the tuberculosis-complex of bacteria. The numbers 9/9 indicate that there are 9 sequences available from the Tuberculosis-complex of bacteria and all 9 of them contain these CSIs. However, these CSIs are lacking in the homologs from all other mycobacteria as well as other examined bacteria. The homologs of these proteins, or the CSI-containing regions of these proteins, are not found in human. The dashes (-) in different sequence alignments show identity with the aa present on the top line. Mutational studies indicate that both these proteins are essential for the growth of *M. tuberculosis* \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\].](high-throughput-07-00031-g003){#high-throughput-07-00031-f003}

![Partial sequence alignment of a LytR family transcriptional regulatory protein showing a 12 aa long deletion in a conserved region. This deletion is uniquely present in all other *M. tuberculosis* complex of organisms except *Mycobacterium canettii*, which branches earlier in comparison to the other species from this group ([Figure 2](#high-throughput-07-00031-f002){ref-type="fig"}). The dashes (-) indicate identity with the aa present on the top line.](high-throughput-07-00031-g004){#high-throughput-07-00031-f004}

![Structural localization of the CSI in the MurB protein. (**A**) Resolved structure of the UDP-*N*-acetylenolpyruvoylglucosamine reductase (MurB) protein from *M. tuberculosis* (PDB ID: 5JZX) \[[@B72-high-throughput-07-00031]\]. The four aa insertion is highlighted in red. (**B**) A close up of the CSI region from *M. tuberculosis* proteins colored in green, and a homology model of the same protein from *Mycobacterium angelicum*, shown in cyan.](high-throughput-07-00031-g005){#high-throughput-07-00031-f005}

![Structural location of the CSI in the CysH protein. (**A**) Homology model of the 3′-phosphoadenosine 5′-phosphosulfate reductase CysH protein from *M. tuberculosis* (based on PDB ID: 2GOY). The seven aa insertion is highlighted in red and boxed. (**B**) Resolved structure of the CysH protein from *Pseudomonas aeruginosa* (PDB ID: 2GOY). The region homologous to the insert is boxed. (**C**) A close-up of the CSI region in the aligned structures of the two proteins, with CSIs marked in red.](high-throughput-07-00031-g006){#high-throughput-07-00031-f006}
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###### 

Summary of conserved signature indels (CSIs) that are specific for the tuberculosis complex.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                                                                                                Gene Number\                Figure Number                                                                                                              Ins/Del    Location     Mutational Results \#
                                                                                                      (*M. tuberculosis* H37Rv)                                                                                                                                                      
  --------------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------- ------------ ---------------------------
  putative UDP-*N*-acetylenolpyruvoyl-glucosamine reductase (MurB)                                    Rv0482                      [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"}A, [Figure S1](#app1-high-throughput-07-00031){ref-type="app"}   4aa Ins    249--298     Essential

  putative 3′-phosphoadenosine 5′-phosphosulfate reductase (CysH) (PAPS reductase, thioredoxin dep)   Rv2392                      [Figure 3](#high-throughput-07-00031-f003){ref-type="fig"}B, [Figure S2](#app1-high-throughput-07-00031){ref-type="app"}   7aa Ins    17--71       Essential (growth defect)

  transcriptional regulator, LytR family                                                              Rv3840                      [Figure 4](#high-throughput-07-00031-f004){ref-type="fig"}, [Figure S3](#app1-high-throughput-07-00031){ref-type="app"}    12aa Del   50--87       Non-essential

  putative propionyl-CoA carboxylase beta chain 5 ACCD5 (PCCASE)                                      Rv3280                      [Figure S4](#app1-high-throughput-07-00031){ref-type="app"}                                                                1aa Del    172--220     Essential

  O-succinylbenzoic acid-CoA ligase MenE \*                                                           Rv0542c                     [Figure S5](#app1-high-throughput-07-00031){ref-type="app"}                                                                2aa Ins    41--95       Essential

  ligase \*                                                                                           Rv3712                      [Figure S6](#app1-high-throughput-07-00031){ref-type="app"}                                                                4aa Ins    180--234     Essential

  arabinosyltransferase EmbB \*                                                                       Rv3795                      [Figure S7](#app1-high-throughput-07-00031){ref-type="app"}                                                                3aa Ins    747--795     Essential

  GTPase Era                                                                                          Rv2364c                     [Figure S8](#app1-high-throughput-07-00031){ref-type="app"}                                                                1aa Ins    225--283     Essential (growth defect)

  primosome assembly protein PriA                                                                     Rv1402                      [Figure S9](#app1-high-throughput-07-00031){ref-type="app"}                                                                3aa Ins    609--655     Essential

  putative phospho-sugar mutase/MRSA homolog \*                                                       Rv3441c                     [Figure S10](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    43--102      Essential

  polyketide synthase Pks8                                                                            Rv1662                      [Figure S11](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    539--586     Non-essential

  Glutamine-dependent NAD(+) synthetase                                                               Rv2438c                     [Figure S12](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    584--641     Essential

  ribonuclease E                                                                                      Rv2444c                     [Figure S13](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    219--269     Essential

  putative folylpolyglutamate synthase protein (FolC)                                                 Rv2447c                     [Figure S14](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    111--170     Essential

  DNA topoisomerase I TOPA (omega-protein)                                                            Rv3646c                     [Figure S15](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    392--440     Essential

  metal cation transporting ATPase H                                                                  Rv0425c                     [Figure S16](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    963--1014    Non-essential

  Acyltransferase \*                                                                                  Rv1565c                     [Figure S17](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    162--220     Non-essential

  α-amylase                                                                                           Rv2471                      [Figure S18](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    428--477     Non-essential

  hypothetical protein IQ48_14915, partial                                                            Rv0897c                     [Figure S19](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    257--306     Non-essential

  hypothetical protein CAB90_01059 \*                                                                 Rv0938                      [Figure S20](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    422--469     Non-essential

  transcriptional regulator \*                                                                        Rv1186c                     [Figure S21](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    406--457     Non-essential

  hypothetical protein IU12_21070                                                                     Rv0008c                     [Figure S22](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    10--59       Non-essential

  hypothetical protein IU14_19860                                                                     Rv0029                      [Figure S23](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Del    194--250     Non-essential

  membrane protein                                                                                    Rv0051                      [Figure S24](#app1-high-throughput-07-00031){ref-type="app"}                                                               8aa Ins    470--522     Non-essential

  hypothetical protein RN11_1864 \*                                                                   Rv0094c                     [Figure S25](#app1-high-throughput-07-00031){ref-type="app"}                                                               8aa Ins    18--67       Non-essential

  transmembrane protein                                                                               Rv0188                      [Figure S26](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Del    18--55       Non-essential

  hypothetical protein ERS181347_00724                                                                Rv0209                      [Figure S27](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    195--242     Non-essential

  conserved membrane protein                                                                          Rv0210                      [Figure S28](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    10--59       Non-essential

  fructose-bisphosphate aldolase \*                                                                   Rv0365c                     [Figure S29](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    144--193     Non-essential

  anti-sigma K factor                                                                                 Rv0444c                     [Figure S30](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    147--206     Non-essential

  conserved protein of uncharacterised function % 2C possibly exported                                Rv0518                      [Figure S31](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    36--84       Non-essential

  exonuclease V subunit α                                                                             Rv0629c                     [Figure S32](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Del    109--159     Non-essential

  multidrug resistance protein EmrB                                                                   Rv0783c                     [Figure S33](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Del    320--366     Non-essential

  Hypothetical protein ERS024213_05484                                                                Rv0789c                     [Figure S34](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    39--91       Non-essential

  LuxR family transcriptional regulator                                                               RVBD_0890c                  [Figure S35](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    290--328     Non-essential

  polyprenyl-diphosphate synthase GrcC                                                                Rv0989c                     [Figure S36](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Del    205--251     Non-essential

  polyprenyl-diphosphate synthase GrcC                                                                Rv0989c                     [Figure S37](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    94--141      Non-essential

  cold-shock protein                                                                                  Rv1253                      [Figure S38](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Del    220--275     Non-essential

  transcriptional regulator                                                                           Rv1358                      [Figure S39](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    94--152      Non-essential

  hypothetical protein IQ40_04435                                                                     Rv1359                      [Figure S40](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    150--208     Non-essential

  esterase                                                                                            Rv1497                      [Figure S41](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    296--344     Non-essential

  hypothetical protein RN11_1864 \*                                                                   Rv0094c                     [Figure S42](#app1-high-throughput-07-00031){ref-type="app"}                                                               8aa Ins    165--213     Non-essential

  DEAD/DEAH box helicase                                                                              Rv2092c                     [Figure S43](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    579--624     Non-essential

  phosphoglycerate mutase                                                                             Rv2135c                     [Figure S44](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    01--48       Non-essential

  hypothetical protein CAB90_02390                                                                    Rv2137c                     [Figure S45](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Ins    10--54       Non-essential

  putative glycerol-3-phosphate dehydrogenase \*                                                      Rv2249c                     [Figure S46](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    333--380     Non-essential

  GTP-binding protein LepA                                                                            Rv2404c                     [Figure S47](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    298--355     Non-essential

  type I restriction/modification system specificity determinant HsdS                                 Rv2761c                     [Figure S48](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    10--58       Non-essential

  hypothetical protein IQ38_12515, partial                                                            Rv2762c                     [Figure S49](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Del    42--81       Non-essential

  polyketide synthase \*                                                                              Rv2940c                     [Figure S50](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    1311--1359   Non-essential

  lipase                                                                                              Rv2970c                     [Figure S51](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    170--225     Non-essential

  secreted protein                                                                                    Rv3054c                     [Figure S52](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    13--61       Non-essential

  DNA polymerase IV \*                                                                                Rv3056                      [Figure S53](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    208--254     Non-essential

  ATP-dependent DNA helicase \*                                                                       Rv3202c                     [Figure S54](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Del    378--426     Non-essential

  membrane protein                                                                                    Rv3207c                     [Figure S55](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    207--256     Non-essential

  ATPase                                                                                              Rv3220c                     [Figure S56](#app1-high-throughput-07-00031){ref-type="app"}                                                               1aa Ins    215--269     Non-essential

  DNA glycosylase \*                                                                                  Rv3297                      [Figure S57](#app1-high-throughput-07-00031){ref-type="app"}                                                               4aa Ins    80--132      Non-essential

  hypothetical protein IQ47_16905, partial \*                                                         Rv3394c                     [Figure S58](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    78--123      Non-essential

  hydrolase \*                                                                                        Rv3400                      [Figure S59](#app1-high-throughput-07-00031){ref-type="app"}                                                               3aa Ins    141--186     Non-essential

  hypothetical protein RN11_1864 \*                                                                   Rv0094c                     [Figure S60](#app1-high-throughput-07-00031){ref-type="app"}                                                               8aa Ins    19--68       Non-essential

  acyl-CoA dehydrogenase FadE27                                                                       Rv3505                      [Figure S61](#app1-high-throughput-07-00031){ref-type="app"}                                                               8aa Ins    162--211     Non-essential

  oxidoreductase \*                                                                                   Rv3742c                     [Figure S62](#app1-high-throughput-07-00031){ref-type="app"}                                                               11aa Del   25--65       Non-essential

  hypothetical protein IQ42_20035 \*                                                                  Rv3912                      [Figure S63](#app1-high-throughput-07-00031){ref-type="app"}                                                               2aa Del    113--159     Non-essential
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\# Inferences whether the genes encoding different proteins are essential or not required for in vitro growth of *M. tuberculosis* H37Rv are based on the results from Himar1 based transposon mutagenesis reported in literature \[[@B45-high-throughput-07-00031],[@B46-high-throughput-07-00031]\], \* Some exceptions are seen for these CSIs.
